CD8A and bone cancer: To test whether systemic STING activation can promote CD8+ T-cell infiltration into the immunosuppressive tumor microenvironment of the bone marrow in our bone cancer model, mice were administered DMXAA (20 mg/kg i.p.)at d3 and d7 and bone marrow was collected from tumor-bearing femora 24 h after the second DMXAA injection for analysis of tumor-infiltrating lymphocytes (TILs) by flow cytometry (gating strategy provided in Supplementary Fig. S7).